Neuroprotective Effect of NO-Delivery Dinitrosyl Iron Complexes (DNICs) on Amyloid Pathology in the Alzheimer's Disease Cell Model.
Wen-Han ChuangYu-Ting ChouYi-Hong ChenTing-Han KuoWen-Feng LiawTsai-Te LuChih-Fei KaoYun-Ming WangPublished in: ACS chemical neuroscience (2023)
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive impairment, memory loss, and behavioral deficits. β-amyloid 1-42 (Aβ 1-42 ) aggregation is a significant cause of the pathogenesis in AD. Despite the numerous types of research, the current treatment efficacy remains insufficient. Hence, a novel therapeutic strategy is required. Nitric oxide (NO) is a multifunctional gaseous molecule. NO displays a neuroprotective role in the central nervous system by inhibiting the Aβ aggregation and rescuing memory and learning deficit through the NO signaling pathway. Targeting the NO pathway might be a therapeutic option; however, NO has a limited half-life under the biological system. To address this issue, a biomimetic dinitrosyl iron complex [(NO) 2 Fe(μ-SCH 2 CH 2 COOH) 2 Fe(NO) 2 ] ( DNIC-COOH ) that could stably deliver NO was explored in the current study. To determine whether DNIC-COOH exerts anti-AD efficacy, DNIC-COOH was added to neuron-like cells and primary cortical neurons along with Aβ 1-42 . This study found that DNIC-COOH protected neuronal cells from Aβ-induced cytotoxicity, potentiated neuronal functions, and facilitated Aβ 1-42 degradation through the NO-sGC-cGMP-AKT-GSK3β-CREB/MMP-9 pathway.
Keyphrases
- signaling pathway
- nitric oxide
- cerebral ischemia
- cognitive impairment
- pi k akt
- traumatic brain injury
- cognitive decline
- epithelial mesenchymal transition
- drug delivery
- cell proliferation
- induced apoptosis
- spinal cord
- metal organic framework
- high glucose
- cell therapy
- subarachnoid hemorrhage
- room temperature
- cerebrospinal fluid
- bone marrow
- drug induced
- protein kinase
- iron deficiency
- visible light
- combination therapy